Prospective evaluation of serum tissue inhibitor of metalloproteinase 1 and carbonic anhydrase IX in correlation to circulating tumor cells in patients with metastatic breast cancer

Table 5 Univariate and multivariate anlaysis for PFS and OS

	PFS Univariate Pvalue	Multivariate Pvalue	HR	95% CI	OS Univariate Pvalue	Multivariate Pvalue	HR	95% CI
CAIX-levels Elevated vs. non elevated	< 0.01	0.06	1.38	0.99 - 1.92	*< 0.01*	*.04*	*1.68*	*1.02 - 2.77*
TIMP levels Elevated vs. non elevated	< 0.01	0.21	1.26	0.88 - 1.80	< 0.01	.09	1.55	0.93 - 2.58
Therapy line > 1^st line vs. 1^st line	*< 0.01*	*< 0.01*	*2.61*	*1.84 - 3.70*	*< 0.01*	*< 0.01*	*2.61*	*1.45 - 4.70*
Grading 3 vs. 1/2	0.49	-	-	-	0.41	-	-	-
Menopusal status Premeno vs. postmeno	0.06	-	-	-	0.49	-	-	-
ER status Negative vs. positive	*0.03*	*0.01*	*1.51*	*1.90 - 2.10*	0.21	-	-	-
PR status Negative vs. positive	0.07	-	-	-	0.57	-	-	-
HER2 status Negative vs. positive	0.17	-	-	-	0.40	-	-	-
Number of metastatic sites Multiple vs. single	< 0.01	*0.02*	*1.52*	*1.08 - 2.15*	< 0.01	0.27	1.37	0.78 - 2.40
CTC count ≥ 5 cells vs. < 5 cells	0.12	-	-	-	*< 0.01*	*< 0.01*	*2.48*	*1.46-4.36*

CAIX, carbonic anhydrase IX; CI, confidence interval; CTC, circulating tumor cell; ER, estrogen receptor; HER, human epidermal growth factor receptor; HR, hazard ratio; OS, overall survival; PFS, progression-free survival; PR, progesterone receptor; TIMP, tissue inhibitor of metalloproteinase.

ISSN: 1465-542X